Sulfoxone
Chemical compound
- J04BA03 (WHO)
- [4-[4-(sulfinomethylamino) phenyl] sulfonylphenyl] aminomethanesulfinic acid
- 144-75-2
Y
- 8954
- DB01145
N
- 8610 Y
- 57OWB0Q221
- D02521 Y
- ChEMBL1200580 N
- DTXSID80162594
- Interactive image
- [Na+].[Na+].[O-]S(=O)CNc1ccc(cc1)S(=O)(=O)c2ccc(NCS([O-])=O)cc2
InChI
- InChI=1S/C14H16N2O6S3.2Na/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20;;/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20);;/q;2*+1/p-2Y
- Key:AZBNFLZFSZDPQF-UHFFFAOYSA-LY
N
Y (what is this?) (verify)Sulfoxone or aldesulfone sodium is an anti-leprosy drug.[1] It is also known as diasone. Sulfoxone sodium was introduced in Japan in 1948.[2] Ernest Muir introduced it to Western use while serving as superintendent of the Chacachacare Leprosarium on Trinidad in the Caribbean.[3]
References
- ^ "Sulfoxone".
- ^ Ozawa H, Maruyama Y (2002). "[A 50-year history of new drugs in Japan: the developments of antileprosy drugs and their epidemiological aspects]". Yakushigaku Zasshi. 37 (1): 76–83. PMID 12412600.
- ^ Browne, Stanley George (1974), "Ernest Muir, C.M.G., C.I.E., M.D. (Edin.), F.R.C.S., LL.D. 1880–1974" (PDF), International Journal of Leprosy, vol. 42, no. 4, Bauru: International Leprosy Association, pp. 457–458, PMID 4617724.
- v
- t
- e
| Rifamycins/ RNA polymerase inhibitor | |
|---|---|
| Antifolates/DSI |
|
| ASA | |
| Topoisomerase inhibitors/ quinolones |
| Aminoglycosides | |
|---|---|
| Oxazolidone | |
| Polypeptide antibiotics |
| Peptidoglycan layer |
|
|---|---|
| Arabinogalactan layer |
|
| Mycolic acid layer |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
